8-K: BIO-key International Faces Nasdaq Delisting Threat Due to Late Financial Filings

BIO-key International has received a second notice from Nasdaq for failing to file its quarterly report, adding to previous concerns about its annual report, and faces a potential delisting if it does not submit a compliance plan.

Summary

• BIO-key International received a notice from Nasdaq on May 22, 2024, stating they are not in compliance with listing rules due to the late filing of their quarterly report for the period ending March 31, 2024.
• This notice follows a previous notification on April 17, 2024, regarding the late filing of their annual report for the year ended December 31, 2023.
• The company had previously filed a notification of late filing on May 16, 2024, citing unreasonable effort and expense as reasons for the delay.
• BIO-key is currently restating its financial statements for multiple periods in 2023, which has further delayed the completion of the required reports.
• The company has until June 17, 2024, to submit a plan to regain compliance, and if accepted, could receive an extension until October 14, 2024, to file the necessary reports.
• BIO-key intends to file the required reports as soon as practicable and regain compliance with Nasdaq listing requirements.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's non-compliance with Nasdaq listing rules, the need to restate financial statements, and the risk of delisting. The delays and potential accounting issues raise significant concerns.

Positives

• The notification letter has no immediate effect on the listing or trading of the company's stock.
• The company intends to file the required reports as soon as practicable and regain compliance with Nasdaq listing requirements.

Negatives

• BIO-key is not in compliance with Nasdaq listing rules due to late financial filings.
• The company is restating financial statements for multiple periods in 2023, indicating potential accounting issues.
• There is a risk of delisting if the company fails to submit an acceptable compliance plan or meet the extended deadline.

Risks

• The company faces the risk of delisting from Nasdaq if it does not regain compliance.
• The restatement of financial statements could reveal material adjustments and impact investor confidence.
• There are potential commercial, reputational, and regulatory risks due to non-compliance with SEC and Nasdaq reporting requirements.
• The company has temporarily lost the use of a Registration Statement on Form S-3 to register securities.
• There is a risk of disruption to the business if material weaknesses in internal controls are not remediated in 2024.

Future Outlook

The company intends to file the required reports as soon as practicable and regain compliance with Nasdaq listing requirements. They are working on a plan to submit to Nasdaq by June 17, 2024, and if accepted, may receive an extension until October 14, 2024.

Management Comments

• The company intends to file the Form 10-Q and the Form 10-K with the SEC as soon as practicable and regain compliance with Nasdaq's continued listing requirements.

Industry Context

The biometric technology industry is competitive, and BIO-key's non-compliance issues could negatively impact its reputation and investor confidence. Timely and accurate financial reporting is crucial for maintaining investor trust and market standing.

Comparison to Industry Standards

• Many companies in the technology sector, especially those listed on major exchanges like Nasdaq, are expected to adhere to strict reporting deadlines.
• Failure to meet these deadlines, as seen with BIO-key, is generally viewed negatively by investors and can lead to increased scrutiny.
• Companies like Okta, Ping Identity, and ForgeRock, which are also in the identity and access management space, typically maintain timely financial reporting, setting a benchmark for BIO-key to meet.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty due to the company's financial and compliance issues.
• Customers and partners may be concerned about the company's stability and reliability.
• Creditors may be wary of lending to the company given the current situation.

Next Steps

• BIO-key needs to submit a plan to regain compliance to Nasdaq by June 17, 2024.
• The company must file its delayed Form 10-Q and Form 10-K as soon as practicable.
• BIO-key needs to complete the restatement of its financial statements for the affected periods in 2023.

Key Dates

Keywords

Nasdaq, delisting, non-compliance, financial reporting, SEC, Form 10-Q, Form 10-K, restatement, compliance plan, BIO-key